Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tobias Melton Axelsen

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Molecular Genetics and Metabolism Reports|July 21, 2021
Case report: 'AARS2 leukodystrophy'Tobias Melton Axelsen, Tzvetelina Lubenova Vammen, Mads Bak, et al.
Toxicology Reports|February 3, 2025
Prolonged sedation and unconsciousness after intoxication with the novel semisynthetic cannabinoid hexahydrocannabioctyl (HHC-C8): Two case descriptionsRagnar Thomsen, Tobias Melton Axelsen, Nicoline Løkken, et al.
Ugeskrift for Laeger|September 1, 2015
[Optogenetics brings hidden neural mechanisms into the light and could become a future therapy]Tobias Melton Axelsen, Charlotte Amalie Emdal Navntoft, Søren Hofman Christiansen, et al.
Ugeskrift for Laeger|February 14, 2020
[Gene therapy for central nervous system disorders]Kristoffer Nissen, Louise Klem, Rose Jeppesen, et al.
Osteoarthritis and Cartilage|July 3, 2024
A phase 2b double-blind placebo-controlled randomized clinical trial of SB-061, an aggrecan mimetic, in patients with symptomatic knee osteoarthritisAsger R Bihlet, Inger Byrjalsen, Kamilla Mundbjerg, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Molecular Genetics and Metabolism Reports|July 21, 2021
Case report: 'AARS2 leukodystrophy'Tobias Melton Axelsen, Tzvetelina Lubenova Vammen, Mads Bak, et al.
Toxicology Reports|February 3, 2025
Prolonged sedation and unconsciousness after intoxication with the novel semisynthetic cannabinoid hexahydrocannabioctyl (HHC-C8): Two case descriptionsRagnar Thomsen, Tobias Melton Axelsen, Nicoline Løkken, et al.
Ugeskrift for Laeger|September 1, 2015
[Optogenetics brings hidden neural mechanisms into the light and could become a future therapy]Tobias Melton Axelsen, Charlotte Amalie Emdal Navntoft, Søren Hofman Christiansen, et al.
Ugeskrift for Laeger|February 14, 2020
[Gene therapy for central nervous system disorders]Kristoffer Nissen, Louise Klem, Rose Jeppesen, et al.
Osteoarthritis and Cartilage|July 3, 2024
A phase 2b double-blind placebo-controlled randomized clinical trial of SB-061, an aggrecan mimetic, in patients with symptomatic knee osteoarthritisAsger R Bihlet, Inger Byrjalsen, Kamilla Mundbjerg, et al.
Pageof 1